News - Pharmaceutical


Current filters:


Popular Filters

6590 to 6614 of 6830 results

Changing the Indian culture in reporting adverse drug reactions


Adverse drug reactions (ADRs) are the sixth global leading cause of death among hospitalized patients…

Asia-PacificBoehringer IngelheimPharmaceuticalRegulationResearch

Dyax expands Sigma-Tau territories for Kalbitor for $7M upfront


USA-based Dyax Corp (Nasdaq: DYAX) says it has expanded the geographic reach of Defiante Farmaceutica,…

Dyax CorpKalbitorLicensingPharmaceuticalRare diseasesSigma-Tau

Phytopharm “lacking no confidence” in pipeline; will seek partner, say analysts


UK-based Phytopharm (LSE: PYM) has reported successful preclinical studies of Cogane (PYM 50028) in Parkinson’s…


Recommendations for European Medicines Agency communication on medicines; 40 years of PIC/S


A report written by an independent expert has highlighted a number of recommendations to help improve…


Ashland to acquire International Specialty Products for $3.2 billion


USA-based Ashland (NYSE: ASH) has agreed to acquire privately-held International Specialty Products (ISP),…

AshlandInternational Specialty ProductsMergers & AcquisitionsPharmaceutical

UNICEF decision to make vaccine prices public likely to have major impact on developing country markets


In a bid to increase transparency and stimulate competition to bring down the prices of vaccines needed…


MAP Pharma files NDA with US regulator for Levadex in migraine


MAP Pharmaceuticals (Nasdaq: MAPP) has submitted a New Drug Application to the US Food and Drug Administration…

LevadexMAP PharmaceuticalsNeurologicalNorth AmericaPharmaceuticalRegulation

New legislation to fight against falsified medicines adopted by EU


The European Union Council on Friday formally adopted new legislation aimed at protecting patients against…


US FDA approves Optimer’s Dificid for C. difficile infection


Following a positive advisory panel recommendation last month, the US Food and Drug Administration has…

Antibiotics and Infectious diseasesCubist PharmaceuticalsDificidNorth AmericaOptimer PharmaceuticalsPharmaceuticalRegulation

AstraZeneca gains rights to Heptares GPCR drug for $6.25 million upfront


Anglo-Swedish drug major AstraZeneca (LSE: AZN) revealed this morning that it has entered a four-year…

AstraZenecaDermatologicalsHeptares TherapeuticsLicensingNeurologicalPharmaceuticalResearch

Chiesi, Eli Lilly and Bayer named for breaches of the ABPI Code of Practice


The UK subsidiaries of Italy’s Chiesi, US drug major Eli Lilly (NYSE: LLY) and Germany’s Bayer…

BayerChiesi FarmaceuticiEli LillyEuropeLevitraNeurologicalPharmaceuticalRegulationReproductiveYasmin

Sanofi enters accord with DNDi to generate new drugs for neglected tropical diseases


French drug major Sanofi (Euronext: SAN) and Drugs for Neglected Diseases initiative (DNDi), a not-for-profit…

PharmaceuticalResearchSanofiTropical diseases

Roche joins forces with ChemRar on developing new antithrombotic drug for Russia


Swiss pharmaceutical major Roche (ROG: SIX) and Russian TeaReks company, a subsidiary of ChemRar, Roche's…

Cardio-vascularChemRar Hi-TechEuropeLicensingPharmaceuticalRocheTeaReks

German pharma hails progress against multiple sclerosis


Multiple sclerosis (MS) sufferers should soon have access to a range of drugs that offer better protection…

EuropeMarkets & MarketingNeurologicalPharmaceuticalResearch

Important implications of Abbott win in US patent ruling


US health care major Abbott Laboratories (NYSE: ABT) last week won a US appeals court ruling that will…

Abbott LaboratoriesLegalNorth AmericaPatentsPharmaceutical

Amylin wins first round in squabble with Lilly over diabetes link with Boehringer


In an initial win for US biotech firm Amylin Pharmaceuticals (Nasdaq: AMLN), the US District Court for…

AmylinBoehringer IngelheimDiabetesEli LillyExenatide InjectionLegallinagliptinNorth AmericaPharmaceuticalTradjenta

Efficacy and stroke concerns halt trial of Abbott cholesterol drug Niaspan combo


US health care major Abbott Laboratories (NYSE ABT) has halted its AIM-HIGH clinical trial of Niaspan…

Abbott LaboratoriesCardio-vascularNiaspanPharmaceuticalResearchSimvastatin

Canada’s Quebec Province overhauls cancer drug evaluation


The Canadian Province of Quebec, which has the highest incidence of new cancer cases in the country,…

North AmericaPharmaceuticalRegulation

German approval for GW and Almirall’s Sativex for spasticity due to MS


Spain’s leading drugmaker Almirall (ALM) and UK-based originator of the cannabis based product GW…

AlmirallEuropeGW PharmaceuticalsNeurologicalPharmaceuticalRegulationSativex

Several abstracts on gout reveal true burden of disease and highlight promising new treatments


New studies on gout were presented this week at EULAR, the Annual Congress of the European League Against…

allopurinolAnti-Arthritics/RheumaticsKrystexxalesinuradPharmaceuticalRegulationResearchSavient Pharmaceuticals

HAI Europe injects public health perspective into European Research and Innovation Framework


Consumer group Health Action International (HAI) Europe has submitted a response to the European Commission…


Major stakeholders optimistic about future of drug development, but differ on defining value


Biopharmaceutical executives, managed care executives, physicians and patients with chronic illness foresee…

HealthcareNorth AmericaPharmaceuticalResearch

6590 to 6614 of 6830 results

Back to top